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a  b  s  t  r  a  c  t
Juvenile  idiopathic  arthritis  (JIA)  refers  to a heterogeneous  group  of illnesses  that  have  in  common  the
occurrence  of  chronic  joint  inﬂammation  in  children  younger  than  16  years  of  age.  The  diagnosis  is  made
only  on  clinical  assessment.  The  identiﬁcation  of  antibody  markers  could  improve  the  early  diagnosis,
optimizing  the  clinical  management  of  patients.  Type  II collagen  is  one  potential  autoantigen  that  has
been  implicated  in  the  process  of arthritis  development.  The  aims  of  our  study  were  to investigate  the
occurrence  of  anti-type  II  collagen  antibodies  and  also  to  determine  the  avidity  of  the  antibody–antigen
binding.  Ninety-six  patients  with  oligoarticular  or polyarticular  JIA,  13  patients  with  ankylosing  spondyli-
tis  (AS)  and 61  healthy  controls  (HC)  were  tested  for anti-type  II collagen  antibodies  by ELISA  and  avidity
ELISA.  Sensitivity  and  speciﬁcity  were  determined  by  the  receiver  operating  characteristic  (ROC)  curve
analysis.  Forty-two  JIA  patients  (44%)  were  positive  for antibodies  against  type  II collagen.  Its detection
was  signiﬁcantly  higher  in JIA patients  than  in AS patients  (p =  0.006)  and  HCs  (p  < 0.0001).  Furthermore,
anti-type  II collagen  antibody  detection  was  signiﬁcantly  more  frequent  in  patients  with  JIA  of  ≤6  months
duration  (p = 0.0007).  Antibodies  displaying  high  avidity  to  type  II collagen  were  associated  with  disease
activity  (p = 0.004).  This  study  demonstrates  that  antibodies  against  type  II collagen  are  present  in  the
serum  of  patients  with  oligoarticular  and  polyarticular  JIA, being  its  presence  more  prevalent  in  patients
with  early  disease.  It  also  demonstrates  that  JIA patients  with  active  disease  present  antibodies  with  high
avidity  against  type  II collagen.
©  2015  European  Federation  of  Immunological  Societies.  Published  by  Elsevier  B.V.  All  rights  reserved.. Introduction
Juvenile idiopathic arthritis (JIA), the most common chronic
nﬂammatory rheumatic disorder of childhood, is characterized
y the onset of chronic arthritis of unknown etiology in children
ounger than 16 years of age [1]. According to the International
eague of Associations for Rheumatology criteria, JIA comprises
even subtypes, being oligoarticular and polyarticular the most
∗ Corresponding author. Tel.: +55 34 3218 2478; fax: +55 34 3218 2203.
E-mail address: galber.araujo@gmail.com (G.R. Araujo).
ttp://dx.doi.org/10.1016/j.imlet.2015.03.006
165-2478/© 2015 European Federation of Immunological Societies. Published by Elseviecommon [2]. Arthritis that affects four or fewer joints after the
ﬁrst six months of the disease is classiﬁed as persistent oligoar-
ticular JIA. Although sometimes thought of as a benign condition,
persistent oligoarticular JIA may, in fact, lead to a wide spectrum of
outcomes, ranging from complete remission after discontinuation
of medication to development of severe damage to affected joints.
The extended oligoarticular JIA subtype has a worse prognosis and
includes patients who have ﬁve or more joints affected after the
ﬁrst 6 months of disease [3]. Arthritis that affects ﬁve or more joints
during the ﬁrst 6 months of the disease is called polyarticular JIA,
which is classiﬁed as rheumatoid factor-negative (RF−) or rheuma-
toid factor-positive (RF+). JIA also encompasses juvenile psoriatic
r B.V. All rights reserved.
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rthritis, enthesis-related arthritis and systemic arthritis. All JIA
ubtypes are of unknown causes. Diagnosis is based on the com-
ined evaluation of medical history, clinical presentation and, to
ome extent, laboratory abnormalities [4,5].
Type II collagen (CII) is the predominant collagen type in joint
artilage and anti-CII antibodies have been reported to be present
n serum, synovial ﬂuid and eluted from cartilage explants of
heumatoid Arthritis (RA) patients [6,7]. Studies have shown that
ntibodies from patients with RA react to various species of CII such
s chicken, bovine, porcine and humans [6,8,9]. However, few stud-
es have evaluated the presence of anti-CII antibodies in JIA [10–13].
vidity ELISA has been used for measuring antibodies–antigen
nteraction in many diseases, including RA, in which different pro-
les could be detected with or without washing with denaturing
gents [6,14–16]. There are no published studies evaluating the
vidity of anti-CII antibodies in JIA.
In the present study we investigated whether antibodies present
n serum of children with oligoarticular and polyarticular JIA reacts
ith type II collagen. In addition, we measured the level of avidity
etween type II collagen and IgG antibodies by using the avidity
LISA assay.
. Materials and methods
.1. Patients
For this study, serum samples were obtained from Brazilian and
ortuguese donors. A total of 96 patients (72 female and 24 male,
ean age 13.6 ± 6.8 years) who fulﬁlled the diagnostic criteria for
ligoarticular and polyarticular JIA, according to the International
eague of Associations for Rheumatology [2], 13 patients with anky-
osing spondylitis (AS) were used as an inﬂammatory rheumatic
isease control (2 female and 11 male, mean age 49.3 ± 7.9 years)
nd 61 Healthy Controls (HC) (41 female and 20 male, mean age
1.7 ± 4 years), were enrolled in this study. Twenty-seven (27.8%)
atients had samples collected in the early phase of the disease (≤6
onths duration). Seventy-one (73.2%) patients had active disease
t the time of sample collection. The criteria adopted to classify
ctive disease were that deﬁned by Consolaro et al. [17] and include
 measures: positivity for CRP or ESR into a continuous measure
f inﬂammation; presence of swollen joints; a physician’s global
ssessment of disease activity, and a parent/patient global assess-
ent of well-being.
Serum samples collected from AS patients were used as a
heumatic disease control group and healthy blood donors were
sed as the HC group. The study protocol involving Brazilian
atients was approved by the ethics committee of the Federal
niversity of Uberlândia whereas the study protocol involving Por-
uguese patients was approved by the ethics committees of the
entro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisbon
cademic Medical Centre. The Portuguese samples were obtained
rom the Biobanco-IMM, Lisbon Academic Medical Centre. After
pproval of the consent procedure by the ethics committee, writ-
en informed consent was obtained from every parent of each child
ncluded in this study. The school-aged children provided their ver-
al and written informed consent to participate in this study, while
hildren under 6 years of age only provided their verbal informed
onsent. After signed all informed consent were scanned and the
riginals were ﬁled. The study was conducted in accordance with
he Declaration of Helsinki..2. Blood tests for inﬂammation detection
C-reactive protein (CRP) detection was determined by latex
gglutination test (LAT) and a value of ≥0.8 mg/dl was  consideredLetters 165 (2015) 20–25 21
elevated. Latex ﬁxation test was utilized for the detection of IgM
RF positivity and erythrocyte sedimentation rate (ESR) was  deter-
mined by modiﬁed Westergren technique and considered elevated
at ≥15 mm/h.
2.3. ELISA and avidity ELISA
For antibody analysis we  used serum samples stored at −80,
collected between 2011 and 2014. The best serum dilution, CII con-
centration, coating/blocking/washing buffers and anti-Human IgG
were determined after several tests. The best ELISA condition for
CII measurement was  chosen based on the difference of reactiv-
ity between patients with JIA and HCs. ELISA and avidity ELISA
were performed simultaneously. The avidity of CII-speciﬁc IgG anti-
bodies was determined as previously described [18], with some
modiﬁcations. Brieﬂy, 96-well microtiter plates (NUNC MaxiSorp)
were coated overnight at 4 ◦C with bovine CII 1.5 g/ml (Becton
Dickinson Biosciences, San Jose, CA) previously diluted in 0.06 M
carbonate buffer (pH 9.6). To verify the presence of cross-reaction
between antibodies and the ELISA plate, each serum sample was
tested alone as blank control (without CII). The microplates were
blocked with PBS supplemented with 3% of Bovine Serum Albu-
min  (BSA) for 1 h at 37 ◦C. Serum samples diluted at 1:100 in
PBS–BSA 1% plus 0.05% Tween 20 were added in duplicate on
separate plates. After incubation for 1 h at 37 ◦C, the plates were
washed with PBS Tween 0.05% and then subjected to differen-
tial washing as follows: one plate was  incubated with 6 M urea
solution diluted in PBS for 10 min, while the other plate was
incubated with PBS Tween 0.05% for 10 min. Anti-CII antibodies
were detected using horseradish peroxidase-conjugated anti-IgG
(Sigma Chemical Co., St. Louis, Mo.) diluted 1:1000 and incubated
for 1 h at 37 ◦C. The reaction was revealed with a substrate solu-
tion consisting of ortho-phenylenediamine (Sigma Chemical Co.)
at 1 mg/ml  in 0.01 M citrate–phosphate buffer (pH 5.0) and 0.03%
H2O2. After incubation for 15 min  at room temperature, the reaction
was stopped with 2 N H2SO4 and read at 492 nm.
For ELISA analysis, the ﬁnal optical density (OD) was  normalized
by the ratio of OD readings for each JIA and AS sample divided by
the mean of OD value obtained by the HC group. Receiver operat-
ing characteristic (ROC) curve was constructed comparing the ELISA
results from JIA with HC group. Based on the ROC curve, a cut-off
point was determined as the value corresponding to the highest
sensitivity without lowering the speciﬁcity. Differences in anti-
CII antibodies reactivity between JIA patients and control groups
are expressed in Reactivity index (RI), which was calculated based
on the cut-off point (RI = normalized OD of each sample/cut-off).
Samples with RI > 1.49 (cut-off) were considered positive.
The criteria adopted to classify the avidity index (AI) were
deﬁned by Marcolino et al. [18]. AIs were calculated as the ratio
between the absorbance (Abs) obtained for the plate washed with
urea (U+) and the plate without urea (U−), and was expressed as a
percentage: AI (%) = Abs(U+)/Abs(U−) × 100. Avidity index was  arbi-
trarily deﬁned as: less than 30%, which was considered low avidity,
between 30% and 60%, classiﬁed as average avidity and higher than
60%, corresponding to high avidity. Data were presented as a mean
value ± standard deviation.
2.4. Statistical analysis
Unpaired t test with Welch’s correction was used to evaluate the
differences among JIA vs HC and JIA vs AS groups. Kruskall–Wallis
test was used when three or more groups were compared. ELISA
data were normalized based on the overall average absorbance
obtained in the detection of anti-CII antibodies in the HC group.
Cut-off that allowed best sensitivity and speciﬁcity was determined
using the ROC curve. The area under the curve (AUC) was also
22 G.R. Araujo et al. / Immunology Letters 165 (2015) 20–25
Table  1
Demographic and laboratory features of the studied population.
Juvenile idiopathic arthritis = 96 p-Value (between
JIA subtypes)
Ankylosing
spondylitis
Healthy children
Persistent
oligoarticular
Extended
oligoarticular
Polyarticular
RF−
Polyarticular
RF+
n (B/P) 41 (21/20) 15 (8/7) 25 (5/20) 15 (6/9) 13 (0/13) 61 (38/23)
Gender (F/M) 31/10 10/5 21/4 11/4 2/11 41/20
Mean  age ± SD 10.5 ± 6.8 12.8 ± 8 14.1 ± 12 22.7 ± 14 0.0038 49.3 ± 7.9 11.7 ± 4
Mean  disease duration
(years) ± SD
6.2 ± 5.6 9.1 ± 5.5 10.1 ± 8.1 16 ± 14.2 NS 12 ± 9.1
CRP  ± SD (mg/dl)
Positive/negative
1.4 ± 1.8
9/32
1.1 ± 0.9
7/8
0.9 ± 1.2
6/19
2.2 ± 1.3
8/7
NS 2.7 ± 0.8
ESR  ± SD (mm/h)
Positive/negative
20.1 ± 18
30/11
19.5 ± 10.7
10/5
20.8 ± 14.8
14/9
19.6 ± 12.7
11/4
NS Missing
n, number of subjects; B, Brazilian population; P, Portuguese population; F, female; M,  male; SD, standard deviation; CRP, C-reactive protein; ESR, erythrocyte sedimentation
rate;  RF, rheumatoid factor; NS, not signiﬁcant. p < 0.05 is statistically signiﬁcant. Variables are expressed as means ± SD. Differences among groups were assessed by
Kruskal–Wallis test.
Fig. 1. Anti-collagen type II antibodies detection by ELISA. (A) Detection of anti-CII antibodies in serum samples from JIA patients (96), AS patients (13) and healthy children
(61)  by ELISA and the respective ROC curve (B). The area under the curve (AUC), cut-off, sensitivity (se), speciﬁcity (sp) and corresponding p-value are indicated inside
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Nhe  graph. (C) Anti-CII antibody levels in patients with early and established JIA. T
ample/cut-off.
etermined. Correlations were assessed using Pearson’s correla-
ion (r). A value of p < 0.05 was considered statistically signiﬁcant.
ata were analyzed by using the GraphPad software package 5.0
GraphPad Software Inc., San Diego, USA).
. Results
.1. Demographic characteristics
The studied population is presented in Table 1. At the time
f samples collection, 73 JIA patients were receiving treatment.
hirty-nine (40.6%) were receiving treatment with non-steroidal
nti-inﬂammatory drugs, 46 (47.9%) were on treatment with dis-
ase modifying anti-rheumatic drugs and 13 (13.5%) were receiving
reatment with biologic agents. Nine (9.4%) patients were untreated
ecause it was their ﬁrst visit to the rheumatology clinic at the
ime of sample collection or because they were in disease remis-
ion. Fifteen (15.6%) patients were RF positive (mean concentration
f 91 ± 260 IU/ml). A total of 30 (31.2%) patients had raised CRP
able 2
ositivity for anti-collagen type II antibodies in the studied population.
Juvenile idiopathic arthritis 
Persistent
oligoarticular n = 41
Extended
oligoaritular n = 15
Polyarticular RF−
n = 25
Reactivity index 1.35 ± 0.5 1.53 ± 0.3 1.6 ± 0.5 
Positivity n (%) 16 (39%) 7 (46.6%) 10 (40%) 
S, not signiﬁcant. p < 0.05 is statistically signiﬁcant. Variables are expressed as means ± rizontal bar indicates the cut-off (1.49). Reactivity index = normalized OD of each
(mean concentration of 1.4 ± 1.3 mg/dl) and 65 (67.7%) had raised
ESR (mean concentration 20.2 ± 10.7 mm/h). JIA patients had mean
disease duration of 10 ± 7 years.
3.2. Immunoreactivity of collagen type II against IgG from JIA
patients and controls
Anti-CII antibodies levels were signiﬁcantly higher in JIA than
in AS patients (p = 0.006) and HC group (p < 0.0001) (Fig. 1A and B).
We found that 42 (44%) JIA patients were positive to CII in ELISA
(RI = 1.920 ± 0.3; AUC = 0.856; p < 0.0001). Although we observed
differences in positivity across JIA subtypes, no signiﬁcant dif-
ferences were observed in the levels of anti-CII reactivity. The
performance of the test was  evaluated for sensitivity and speci-
ﬁcity and found to be 45.3% and 93.4%, respectively. On  the other
hand, we found that 2 AS patients (15%) and 4 HCs (6.5%) were also
anti-CII positives. These results are summarized in Table 2.
We  did not observe signiﬁcant differences in reactivity to CII in
JIA patients across gender, ethnicity, number of joints affected or
p-Value Ankylosing
spondylitis n = 13
Healthy children
n = 61
Polyarticular RF+
n = 15
1.6 ± 0.4 NS 1.1 ± 0.4 0.85 ± 0.3
9 (60%) 2 (15%) 4 (6.5%)
SD. Differences among JIA subtypes were assessed by Kruskal–Wallis test.
G.R. Araujo et al. / Immunology Letters 165 (2015) 20–25 23
F rea. Optical density differences before (U−) and after (U+) treatment with urea are shown
f mples from individual patients are identiﬁed by a line between points.
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Fig. 3. Avidity proﬁle of anti-collagen type II antibodies. (A) Avidity proﬁles of anti-
CII  antibodies observed in 96 patients with oligoarticular and polyarticular forms ofig. 2. Anti-CII antibody levels detected in JIA before and after treatment with 6 M u
or  each patient separately for each JIA subtype (A, B, C, D). The paired U− and U+ sa
herapy. There was no statistically signiﬁcant difference between
he Portuguese and the Brazilian population. JIA patients with ≤6
onths of disease duration that were positives for anti-CII anti-
odies (n = 16) presented levels of anti-CII antibodies signiﬁcantly
igher (p = 0.0007) than patients with established disease (n = 26)
Fig. 1C). Of interest, 32 (76%) of the anti-CII positive patients had
ctive disease. Anti-CII antibodies were directly correlated with RF
Pearson r = 0.7207, p < 0.005). No correlations were found when
evels of anti-CII antibodies were analyzed separately for the val-
es of CRP, ESR and the number of inﬂamed joints. However, a
3-year-old girl with polyarticular RF+, who presented inﬂamma-
ion in more than 5 joints, high CRP concentration (2.8 mg/dl),
ncreased ESR (38 mm/h), and very high levels of rheumatoid factor
1118.80 Ul/ml), presented the highest levels of anti-CII antibodies
n ELISA (RI = 2.9).
.3. Avidity of anti-CII antibodies and controls
The levels of anti-CII antibodies detected in the serum from dif-
erent subtypes of JIA without and after treatment with 6 M urea
re shown in Fig. 2. In the serum samples from JIA patients, AIs
anged from 9.6% to 97% (mean of 52.2% ± 18) (Fig. 3A). Forty-
ix (47.9%) samples presented antibodies with high avidity to CII
mean of 73.9% ± 10.4), 39 (40.6%) samples presented antibodies
ith medium avidity (mean of 47.4% ± 8.1) and 11 (11.4%) sam-
les presented antibodies with low avidity (mean of 24.1% ± 5.3).
erum samples from AS patients presented AIs ranging from 20.3%
o 52% (mean of 36.2% ± 7.9), with most patients displaying anti-
odies with medium avidity to CII. Serum from HC presented AIs
anging from 7% to 47.1% (mean of 26% ± 8.5), with most of patients
isplaying antibodies with low avidity to CII. When JIA patients
ere subdivided according to different populations, gender, eth-
icity, treatment or disease duration, no signiﬁcant difference was
bserved in the avidity index in any disease subtype. In the group
JIA,  13 patients with AS and 61 HCs. (B) Antibodies displaying high avidity to type
II  collagen in patients with inactive and active JIA. The avidity index values were
deﬁned as: <30% = low avidity; between 30% and 60% = medium avidity; >60% = high
avidity. Avidity indexes are indicated as lines.
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isplaying antibodies with high avidity against CII, we observed
hat patients with active disease (n = 32; mean of 76.5% ± 11) at
he time of sample collection presented AIs signiﬁcantly higher
n comparison with patients in inactive/remission disease (n = 14;
ean of 68% ± 5.6) (p = 0.004) (Fig. 3B). Interestingly, polyarticu-
ar JIA patients presented AIs signiﬁcantly higher than other JIA
ubtypes (p = 0.006). We  did not observe signiﬁcant association
etween high avidity antibodies and levels of RF for polyarticular
IA patients. The avidity of antibodies toward CII was signiﬁcantly
igher in JIA patients when compared with AS (p < 0.0001) or HC
roup (p < 0.0001).
. Discussion
Most of what we know about autoimmune response to CII
omes from experimental disease models. Particularly, from the
ollagen-induced arthritis (CIA) experimental models, obtained by
mmunization with autologous or heterologous type II collagen
ith adjuvant [19]. Several studies have attempted to identify anti-
odies to CII in RA [6–9,20–22], however, only a small number of
ublished studies aimed to determine the prevalence of anti-CII
ntibodies in JIA patients [10–13]. The current work reports the
ccurrence and avidity of anti-type II collagen antibodies in patients
ith JIA compared with healthy individuals.
Different compositions of type II collagen have been used as the
ntigen to antibodies detection in RA and JIA in its native or dena-
ured forms. The vast majority of published studies about the occur-
ence of anti-CII in JIA and RA, aimed to determine the prevalence of
ntibodies to citrullinated CII [12,23,24]. Antibodies to native citrul-
inated CII have already been detected in 78.5% of RA [24] and 24%
f JIA patients [12]. Antibodies to native human CII were detected
n 20% [25] and 70% of RA [11], 47% [11] of JIA patients and recently,
n 3.1% [13]. Antibodies to native bovine CII (the same we  have used
n our study) were detected in 31.5% of RA patients [6]. Based on
he most adequate cut-off value determined by the ROC curve, we
ound that 44% of our JIA patients were positives to anti-CII anti-
odies. The positivity of anti-CII antibodies in the AS population
15%) was lower than the results reported in another study [26],
hich showed positivity in 33.3% of the patients. Although anti-CII
ntibodies were present in the AS group its detection was much
igher in JIA patients. The differences in the prevalence of anti-CII
n the several published studies may  be due to the different species
f CII used as the antigen to antibodies detection, since studies that
imed to analyze CII speciﬁcity revealed that autoantibodies are
enerally associated with speciﬁc arthritogenic epitopes present
n the CII molecules from different species [27,28]. The different
ethodologies of data analysis (normalization and cut-off determi-
ation), the number of patients in which these anti-CII antibodies
ave been measured, or even patient’s disease activity [6] could
lso have contributed to these heterogeneous results.
Our results also showed increased levels of anti-CII antibodies
n patients with early JIA, with the vast majority of individuals
resenting active disease at the time of sample collection. These
ata are consistent with previous ﬁndings reporting higher fre-
uencies of anti-CII antibodies in early RA [29–31] and recently,
n JIA patients [13]. Similar results were also observed in CIA mod-
ls after arthritis induction by immunization with CII, where the
evels of circulating anti-CII antibodies in MRL/I mice were as well
ighest at 6 months, thus immediately after the development of
rthritis [32]. Anti-CII appearing early in the course of the disease
uggests that these autoantibodies might play a role in JIA phys-
opathology. However, the clinical relevance of its detection in early
IA is still an open question. We  hypothesize that in patients with
arly JIA, high levels of anti-CII antibodies might induce an acute
nﬂammation mediated by surface-bound immune complexes (IC)Letters 165 (2015) 20–25
containing anti-CII, as has already been described in RA [9]. Puri-
ﬁed CII-speciﬁc monoclonal antibodies were shown to induce an
acute form of arthritis in mice [33], which demonstrates that anti-
CII autoantibodies are indeed directly pathogenic in vivo. These
anti-CII antibodies appearing around clinical onset suggests that
these autoantibodies play an early role in the process of disease
development. If it proves to be true, the detection of these antibod-
ies could lead to faster diagnosis and treatment. Our results also
showed a high percentage of anti-CII positive patients presenting
active disease (76%). Taking into account what has already been
reported [34–36], we believe that circulating ICs containing anti-CII
can activate the complement system and stimulate the production
of cytokines of pathogenic importance in the inﬂammatory process,
such as interleukin-1  (IL-1), IL-6, IL-10 and tumor necrosis fac-
tor  (TNF-). This event could perpetuate joint inﬂammation and
consequently maintain the disease activity. This hypothesis is cor-
roborated by Mullazehi et al. [34] who  reported that in RA patients
the production of the cytokines TNF-, IL-1 and IL-8 decreased
after the speciﬁc blockade of ICs containing anti-CII.
Our results also showed a high percentage of anti-CII antibody
positive samples in the group with polyarticular RF+ and also a
direct correlation between anti-CII antibodies and RF. This is in line
with the fact that this subtype corresponds basically to a juvenile
RA onset, with a more persistent and severe course of the disease as
compared to other JIA subtypes [37]. Furthermore, we reported a
patient with polyarticular onset displaying high levels of RF, CRP
and ESR who presented the highest level of anti-CII antibodies.
Although when analyzed separately no correlation between levels
of anti-CII and values of CRP and ESR was  found, these ﬁndings are
in agreement with what has already been reported in RA patients
[7], where levels of anti-CII antibodies were higher in patients with
high CRP and ESR, and partially, with another study [13] involving
JIA patients, where anti-CII antibodies was associated with high
levels of CRP.
In the present study, we calculated the AI of speciﬁc anti-CII
antibodies, determined from the avidity ELISA. A brief 6 M urea
treatment allowed the dissociation of the low-avidity interactions,
retaining the antibodies that bind with higher avidity to CII. This is
the ﬁrst study investigating the nature of anti-CII antibodies avid-
ity in patients with JIA. We have shown that levels of antibodies
displaying high avidity to CII were signiﬁcantly higher in patients
with active disease and in polyarticular patients. The driving force
in the antibody binding and progressive destruction of cartilage is
still obscure. However, it has been demonstrated that anti-CII anti-
bodies form immune complexes with CII joint cartilage that, when
not effectively removed, can activate complement and contribute
to chronic inﬂammation [36]. Treatment-resistant JIA results in
joint destruction, especially in patients with polyarticular subtype,
which have the poorest prognosis with a remission rate of only
15%. More than 50% of JIA patients do not achieve remission despite
treatment and require further rheumatological care as adults [38]. A
possible explanation for the high occurrence of antibodies binding
with high avidity against CII in samples from patients with active JIA
could be that IC’s production is not being blocked properly, result-
ing in active disease. In fact, it has been reported that the blocking
of the complement system resulted in decrease of inﬂammatory
cytokine, showing that complement plays a role in arthritis [36]. If
this proves to be true, a target therapy based on this mechanism
could be highly promising for both RA and JIA.
In conclusion, the present study showed that anti-CII antibod-
ies are present in patients with oligoarticular and polyarticular
forms of JIA. Consistent with RA data, high levels of anti-CII anti-
bodies were detected in patients with JIA of ≤6 months duration,
suggesting that anti-CII antibodies in JIA patients are associated
with the early inﬂammatory process. Patients with active disease
had more frequently high avidity antibodies against CII. Our  data
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